New-onset cardiovascular diseases post SARS-CoV-2 infection in an urban population in the Bronx DOI Creative Commons
Jimmy Lu, Justin Y. Lu, Stephen Wang

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Dec. 28, 2024

Abstract This study investigated the incidence of new-onset cardiovascular disorders up to 3.5 years post SARS-CoV-2 infection for 56,400 individuals with COVID-19 and 1,093,904 contemporary controls without in Montefiore Health System (03/11/2020 07/01/2023). Outcomes were new major adverse event (MACE), arrhythmias, inflammatory heart disease, thrombosis, cerebrovascular disorders, ischemic disease other cardiac between 30 days (up to) index date. Results also compared a pre-pandemic cohort over similar observation duration ( N = 64,541). Cumulative hazard ratios adjusted competitive risks analyzed. Compared controls, hospitalized patients had significantly higher risk developing MACE (aHR 2.29, 95% confidence interval [2.27, 2.31], p < 0.001), arrhythmias 2.54[2.50, 2.58], 5.34[4.79, 5.96], 2.05[2.00, 2.11], 2.31[2.26, 2.35], thrombosis 4.25[4.15, 4.36], 1.89[1.86, 1.92], 0.001). Non-hospitalized slightly 1.04[1.03, 1.06], 1.10[1.08, 1.12], 2.29 [2.03, 2.59], 1.11[1.07, 1.15], 1.13], Race ethnicity mostly not associated increased > 0.05). aHRs as reference those reference. We concluded that incident patients, especially COVID-19, than controls. Identifying factors may draw clinical attention need careful follow-up at-risk individuals.

Language: Английский

Long term outcomes of patients with chronic kidney disease after COVID-19 in an urban population in the Bronx DOI Creative Commons
Jimmy Lu, Justin Y. Lu, Stephen Wang

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 19, 2025

Abstract We investigated the long-term kidney and cardiovascular outcomes of patients with chronic disease (CKD) after COVID-19. Our retrospective cohort consisted 834 CKD COVID-19 6,167 without between 3/11/2020 to 7/1/2023. Multivariate competing risk regression models were used estimate (as adjusted hazard ratios (aHR) 95% confidence intervals (CI)) progression a more advanced stage (Stage 4 or 5) major adverse events (MAKE), (MACE) at 6-, 12-, 24-month follow up. Hospitalized 12 24 months (aHR 1.62 CI[1.24,2.13] 1.76 [1.30, 2.40], respectively), but not non-hospitalized patients, higher compared those Both hospitalized MAKE 12- 24-months 1.73 [1.21, 2.50], 1.77 [1.34, 2.33], 1.31 [1.05, 1.64], MACE increases in CKD. These findings highlight need for close up care therapies that slow this high-risk subgroup.

Language: Английский

Citations

2
Global, regional and national burdens of chronic kidney disease due to T1DM and T2DM among adolescents and young adults aged 10–35 years from 1990–2021: A trend analysis based on the global burden of disease study 2021 DOI

Bingrong Wu,

Zhou Yang, Qing Ni

et al.

Diabetes Research and Clinical Practice, Journal Year: 2025, Volume and Issue: 220, P. 111985 - 111985

Published: Jan. 5, 2025

Language: Английский

Citations

1
Renal long COVID-19: an ongoing debate requiring robust evidence DOI
Heitor S. Ribeiro, Emmanuel A. Burdmann, Luís Yu

et al.

Brazilian Journal of Nephrology, Journal Year: 2025, Volume and Issue: 47(1)

Published: Feb. 24, 2025

Language: Английский

Citations

0
COVID-19 longa renal: um debate em andamento que requer evidências robustas DOI
Heitor S. Ribeiro, Emmanuel A. Burdmann, Luís Yu

et al.

Brazilian Journal of Nephrology, Journal Year: 2025, Volume and Issue: 47(1)

Published: Feb. 24, 2025

Citations

0
Long-Term Outcomes of Patients with Pre-Existing Essential Tremor After SARS-CoV-2 Infection DOI Creative Commons

Rachel Pakan,

Roham Hadidchi,

Yousef Al-Ani

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(24), P. 2774 - 2774

Published: Dec. 10, 2024

Although COVID-19 has been linked to worse outcomes in patients with neurological disorders, its impact on those essential tremor (ET) remains unclear. To investigate clinical of ET and without three a half years post-pandemic. 1074 were evaluated this retrospective study the Montefiore Health System from January 2016 July 2023. Comparisons between positive SARS-CoV-2 polymerase chain reaction test made. Outcomes included post-index date major adverse cardiovascular events (MACEs), new-onset sleep disturbances, fatigue, dyspnea, first-time fall, anxiety, depression, headache, imbalance, mild cognitive impairment, all-cause mortality, adjusted hazard ratios (aHR) adjusting for covariates calculated. had higher prevalence pre-existing type-2 diabetes, anxiety compared COVID-19. was significantly associated risk MACEs, (aHR = 2.39 [1.49, 3.82]), disturbance, 2.12 [1.44, 3.13]), 1.83 [1.27, 2.65]), 1.98 [1.40, 2.80]), 4.76 [2.24, 10.14]), 3.66 [2.02, 6.64]), 2.38 [1.20, 4.70]). not mortality. In ET, increases several long-term health outcomes, but

Language: Английский

Citations

1
New-onset gastrointestinal disorders in COVID-19 patients 3.5 years post-infection in the inner-city population in the Bronx DOI Creative Commons

Sagar Changela,

Samad Ashraf,

Justin Y. Lu

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Dec. 30, 2024

This study examined the incidence, characteristics, and risk factors of new gastrointestinal disorders (GID) associated with SARS-CoV-2 infection up to 3.5 years post-infection. retrospective included 35,102 COVID-19 patients 682,594 contemporary non-COVID-19 without past medical history GID (controls) from Montefiore Health System in Bronx (3/1/2020 7/31/2023). Comparisons were made unmatched propensity-matched (1:2) controls. The primary outcome was which peptic ulcer, inflammatory bowel disease, irritable syndrome, diverticulosis, diverticulitis, biliary disease. Multivariate Cox proportional hazards model analysis performed adjustment for covariates. There 2,228 (6.34%) positive who developed compared 38,928 (5.70%) had an elevated developing (adjusted HR = 1.18 (95% CI 1.12-1.25) controls, after adjusting confounders that smoking, obesity, diabetes, hypertension. These findings underscore need additional research follow-up at-risk individuals post infection.

Language: Английский

Citations

1
New-onset cardiovascular diseases post SARS-CoV-2 infection in an urban population in the Bronx DOI Creative Commons
Jimmy Lu, Justin Y. Lu, Stephen Wang

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Dec. 28, 2024

Abstract This study investigated the incidence of new-onset cardiovascular disorders up to 3.5 years post SARS-CoV-2 infection for 56,400 individuals with COVID-19 and 1,093,904 contemporary controls without in Montefiore Health System (03/11/2020 07/01/2023). Outcomes were new major adverse event (MACE), arrhythmias, inflammatory heart disease, thrombosis, cerebrovascular disorders, ischemic disease other cardiac between 30 days (up to) index date. Results also compared a pre-pandemic cohort over similar observation duration ( N = 64,541). Cumulative hazard ratios adjusted competitive risks analyzed. Compared controls, hospitalized patients had significantly higher risk developing MACE (aHR 2.29, 95% confidence interval [2.27, 2.31], p < 0.001), arrhythmias 2.54[2.50, 2.58], 5.34[4.79, 5.96], 2.05[2.00, 2.11], 2.31[2.26, 2.35], thrombosis 4.25[4.15, 4.36], 1.89[1.86, 1.92], 0.001). Non-hospitalized slightly 1.04[1.03, 1.06], 1.10[1.08, 1.12], 2.29 [2.03, 2.59], 1.11[1.07, 1.15], 1.13], Race ethnicity mostly not associated increased > 0.05). aHRs as reference those reference. We concluded that incident patients, especially COVID-19, than controls. Identifying factors may draw clinical attention need careful follow-up at-risk individuals.

Language: Английский

Citations

0